Hebei Changshan Biochemical Pharmaceutical (300255.SZ): Heparin Sodium Injection obtains Moldova drug registration certificate.

Hebei Changshan Biochemical Pharmaceutical (300255.SZ) announced that the company recently received notice that its drug Heparin Sodium Injection has obtained a drug registration certificate issued by the drug regulatory authority of Moldova. Heparin Sodium Injection is mainly used for the prevention and treatment of thrombotic or embolic diseases (such as myocardial infarction, thrombophlebitis, pulmonary embolism, etc.); disseminated intravascular coagulation (DIC) caused by various reasons; and is also used for anticoagulation treatment during hemodialysis, extracorporeal circulation, catheterization, microvascular surgery, and other procedures, as well as for certain blood specimens or instruments. The obtaining of the registration approval for Heparin Sodium Injection in Moldova will have a certain positive impact on the company's expansion of overseas markets. Currently, the proportion of overseas sales revenue of the company's heparin preparation products to the company's total operating revenue is relatively low.